N/A N=78 Effects of Fatty Acid Delivery on Heart Metabolism and Function in Type 2 Diabetes (T2DM
Diabetes Mellitus, Type II
Primary: Percent Change in Plasma Triglycerides — -2.0; 16.0; -5.0; -5.0 percent change
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=102 Metformin in Overweight Type 2 Diabetes Mellitus
Obesity · Type 2 Diabetes Mellitus
Primary: Change in Weight From Baseline at 12 Months or More — -8.37 Kg — p=<0.05
N/A N=1,523 A Study of the Current Medical Practice and Outcomes in the Treatment of Type 2 Diabetes Mellitus in an Office Setting (MK-0431-199)
Type 2 Diabetes Mellitus
Primary: Change From Baseline for Mean Hemoglobin A1c (HbA1C) — 6.9; -0.5 Percent of glycosylated hemoglobin
Phase 4 N=130 Myocardial Dysfunction in Type 2 Diabetes Mellitus (T2DM)
Type 2 Diabetes · Coronary Heart Disease
Primary: Change in E to A Ratio — 1.04; 1.25 Ratio — p=<0.01
Phase 3 N=127 Vitamin D for Established Type 2 Diabetes (DDM2)
Type 2 Diabetes
Primary: Disposition Index — 0.023; 0.149 index
N/A N=958 Gestational Diabetes Mellitus Trial (GDM)
Diabetes, Gestational
Primary: Number of Participants With Composite Neonatal Morbidity — 149; 163; 62; 55 Participants — p=0.14
Phase 2 N=24 Effect of Momordica Charantia Administration on Type 2 Diabetes Mellitus, Insulin Sensitivity and Insulin Secretion
Diabetes Mellitus Type 2
Primary: Total and First Phase of Insulin Secretion (Insulinogenic Index and Stumvoll Index) After 90 Days — 0.41; 0.23; 1135.7; 309.0 index
N/A N=235 Type 2 Diabetes Exemplar: A Remote Care Service for North West London
Type 2 Diabetes Mellitus
Primary: % Participants Downloading Huma App — 95; 0 Participants
Phase 3 N=46 YH1 in Poorly Controlled Type 2 Diabetes
Type 2 Diabetes
Primary: The Percentage Change in HbA1c Level From Baseline to 12 Weeks — -11.1; 0.0 percentage change
Phase 2 N=36 A Study of the Efficacy of Prolonged-Release Melatonin Versus Placebo in Diabetic Patients Suffering From Insomnia
Diabetes Mellitus, Type 2 · Insomnia
Primary: Sleep Efficiency — 79.5; 83.1 Percentage of time asleep — p=0.04
Phase 3 N=24 Impact of Mulberry Leaf on Type 2 Diabetes
Type 2 Diabetes
Primary: Hemoglobin A1C — -0.39; -0.26 percent — p=0.079
N/A N=1,915 Genetics of Diabetes Audit and Research in Tayside Scotland (DOLORisk Dundee)
Diabetic Neuropathic Pain
Primary: Neuropathic Pain — 482; 461; 560 Participants
N/A N=40 Glycemic Responses to Majia Pomelos in Type 2 Diabetic Patients
Diabetes
Primary: Glycemic Index — 76.79; 86.92 percentage of AUC from GI100 — p=0.005
Phase 2 N=375 A New Oral Treatment For Type II Diabetes Mellitus
Diabetes Mellitus, Type 2
Primary: Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 12 — 0.46; 0.18; -0.07; 0.01 Percentage of HbA1c — p=0.061
N/A N=18 Study of Dapagliflozin on Mitochondrial Dysfunction and Impaired Insulin Signaling/Action
Insulin Sensitivity · Multiple Mitochondrial Dysfunctions Syndrome
Primary: Change in Insulin Sensitivity — 3.18; 3.85; 3.57; 5.22 mg/kg.min per µU/ml
Phase 3 N=699 Treatment Options for Type 2 Diabetes in Adolescents and Youth (TODAY)
Diabetes Mellitus, Type II
Primary: Treatment Failure (Loss of Glycemic Control) — 120; 90; 109; 112 participants
N/A N=58 Preservation of Beta-cell Function in Type 2 Diabetes Mellitus
Type 2 Diabetes Mellitus
Primary: Beta-cell Function - C-peptide AUC (Area Under the Curve) — 2096; 1725 ng*min/mL
Phase 2 N=60 Safety and Efficacy Study of Tesofensine/Metoprolol Treatment in Subjects With Type 2 Diabetes Mellitus
Type 2 Diabetes Mellitus
Primary: Effects of Co-administration of Tesofensine/Metoprolol Treatment vs. Placebo on 24-hour Mean Heart Rate — 67; 70 beats per minutes (BPM) — p=0.004
Phase 4 N=413 This Study Is To Determine If Inhaled Insulin Is Effective In Treating Type 2 Diabetes Mellitus
Diabetes Mellitus, Type 2
Primary: Change From Baseline in Glycosylated Hemoglobin A1c (HbA1c) at Week 26 for the Per Protocol (PP) Population — -2.01; -1.75 percent — p=<0.0001
N/A N=507 Beta-Cell Dysfunction and Insulin Resistance Among Italian Patients With Type 2 Diabetes (MK-0000-113)
Type 2 Diabetes
Primary: Change From Baseline in Homeostatic Model Assessment Fasting Beta Cell Function (HOMA % B) at 4 Years — 50.2; 48.3 Percentage of Beta Cell Function — p=0.24
Phase 1 N=33 Contribution of Hyperinsulinemia vs. Hyperglycemia to Insulin Resistance in Type 1 Diabetes and Maturity Onset Diabetes of the Young, Type 2 (MODY2)
Type 1 Diabetes Mellitus · Maturity-Onset Diabetes of the Young, Type 2 · MODY2
Primary: Whole-body Glucose Utilization (Rd) — 8.5; 11.0; 12.1 mg/kg FFM/min
N/A N=36 Acute Effect of MMT Peel Powder on Glycemic Response, Satiety, and Food Intake in Adults at Risk for Type 2 Diabetes
At Risk of Type 2 Diabetes Mellitus
Primary: Blood Glucose Levels — 5.6; 5.7; 6.7; 7.7 mmol/L — p=<0.001
Phase 3 N=369 A Study In Patients With Type 2 Diabetes Mellitus
Diabetes Mellitus, Type 2
Primary: Median Percent Change From Baseline to Week 6 in LDL-c in FDC and RSG Monotherapy — -39.9; 5.4 Percent change in LDL-c — p=<0.0001
Phase 4 N=36 Sitagliptin + Metformin Compared to Metformin Monotherapy and Placebo in Women With a Recent GDM
Disorder of Glucose Regulation
Primary: Normalization of Glucose Levels — 9; 2; 4 Participants — p=.035
N/A N=60 Comparison Effects Of Different Exercise Approaches On Type 2 DM Women
Type 2 Diabetes
Primary: Glycosylated Hemoglobin Change — 6.82; 7.17; 6.80; 6.33 percentage of glycosylated hemoglobin — p=0.830
Phase 1 N=117 PF-06291874 Multiple Ascending Dose Study In Type 2 Diabetes Mellitus Patients
Diabetes Mellitus, Type 2
Primary: Number of Participants Had Protocol-Defined Total Hypoglycemic Adverse Event (HAE) - Part A — 2; 2; 1; 1 participants
N/A N=14 The Effect of Hypoxia on Type 2 Diabetes and Weight Loss
Type2 Diabetes
Primary: Δ Mean AUC (Area Under the Curve) Plasma [Glucose] — -17.7; 54.9 mmol.min.L-1
N/A N=25 Metformin Versus Insulin in Pregnant Women With Type 2 Diabetes
Pregnancy Complications
Primary: The Number of Participants Who Achieved a Hemoglobin A1C <7% — 5; 12 Participants
Phase 3 N=521 An Investigational Drug Study in Patients With Type 2 Diabetes Mellitus (MK0431-023)
Diabetes Mellitus, Type 2
Primary: Change From Baseline in A1C at Week 18 — -0.48; -0.36; 0.12 percent — p=<0.001
N/A N=55 Type 2 Diabetes and Exercise Function in Single Leg Exercises
Type 2 Diabetes
Primary: Change in Muscle Oxygen Saturation — -10.7127; -8.9149; -12.471; -8.7883 percentage